Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma-Reference-Cited by-同舟云学术

Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma

Published:2013-06-05 Issue:11 Volume:92 Page:1503-1511
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Ferrero Simone,Monitillo Luigia,Mantoan Barbara,Barbero Daniela,Genuardi Elisa,Barbiero Sara,Bernocco Elisa,Caracciolo Daniele,Ruella Marco,Drandi Daniela,Zanni Manuela,Renna Federica,Lobetti Bodoni Chiara,Gueli Angela,Passera Roberto,Musto Pellegrino,Boccadoro Mario,Tarella Corrado,Ladetto Marco

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-013-1797-y.pdf

Reference31 articles.

1. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK (2005) Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23:5019–5026

2. Griffiths R, Mikhael J, Gleeson M, Danese M, Dreyling M (2011) Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood 118:4808–4816

3. Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota SD, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C, Gruppo Italiano Trapianto di Midollo Osseo (GITMO), Intergruppo Italiano Linfomi (IIL) (2008) Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 111:4004–4013

4. Goff L, Summers K, Iqbal S, Kuhlmann J, Kunz M, Louton T, Hagenbeek A, Morschhauser F, Putz B, Lister A, Rohatiner A (2009) Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma. J Clin Oncol 27:6094–6100

5. Pott C, Schrader C, Gesk S, Harder L, Tiemann M, Raff T, Brüggemann M, Ritgen M, Gahn B, Unterhalt M, Dreyling M, Hiddemann W, Siebert R, Dreger P, Kneba M (2006) Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 107:2271–2278

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable Residual Disease Monitoring in Lymphoma;Current Hematologic Malignancy Reports;2023-11-06

2. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study;Journal of Clinical Oncology;2021-10-28

3. Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue;Clinical Lymphoma Myeloma and Leukemia;2021-04

4. Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy;Cancers;2021-01-14

5. Minimal Residual Disease and Survival Outcomes in Patients with Mantle Cell Lymphoma: a systematic review and meta-analysis;Journal of Cancer;2021